Eva Blondeaux
YOU?
Author Swipe
View article: Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies
Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies Open
FP and ovarian protection uptake were markedly higher in Italy than Mexico, possibly reflecting divergent social and healthcare contexts, though cryopreservation remained underutilized in both countries. Improved access to oncofertility se…
View article: Response to: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancer
Response to: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancer Open
View article: Weight Changes during Early Breast Cancer Treatment and Their Association with Survival: An Exploratory Functional Data Analysis of GIM-2 Trial
Weight Changes during Early Breast Cancer Treatment and Their Association with Survival: An Exploratory Functional Data Analysis of GIM-2 Trial Open
Introduction Limited evidence is available on the impact of early breast cancer (EBC) treatments on body weight. Notably, robust data quantifying the magnitude and timing of weight changes during treatment are lacking, and existing finding…
View article: Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses Open
Our results indicate that neoadjuvant/perioperative immunotherapy should be considered the standard. This should be preferred over upfront surgery, also in stage II, PD-L1-negative and squamous histology.
View article: Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers Open
View article: Breastfeeding after breast cancer in young <i>BRCA</i> carriers
Breastfeeding after breast cancer in young <i>BRCA</i> carriers Open
Background We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods This was an international, multicenter, hospital-based, retrospective cohort study …
View article: Cancer Awareness Among People Living with HIV (PLWH): Insights from an Italian Survey of Oncologists and Infectious Disease Specialists
Cancer Awareness Among People Living with HIV (PLWH): Insights from an Italian Survey of Oncologists and Infectious Disease Specialists Open
The results of this survey underscore the opportunity for education, interdisciplinary collaboration, and organizational support to optimize cancer care for PLWH. A Hub&Spoke model could represent a potential facilitation to build-up in th…
View article: Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis
Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis Open
Background Approximately 3% of colorectal cancers (CRCs) are due to Lynch syndrome (LS), a hereditary cancer syndrome caused by pathogenic variants (PVs) in the mismatch repair (MMR) genes. Patients with CRC and LS have elevated lifetime r…
View article: Letter response re: factors associated with first-to-second line attrition among patients with metastatic breast cancer in the real-world
Letter response re: factors associated with first-to-second line attrition among patients with metastatic breast cancer in the real-world Open
View article: Supplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in pre-menopausal women.
View article: Data from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Data from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Purpose:Low-dose tamoxifen 5 mg/day (babytam) for 3 years can decrease the incidence of new breast cancer events in women with breast intraepithelial neoplasia by 42% with limited toxicity, which provides a new treatment option for these d…
View article: Supplementary Table S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Representativeness of Study Participants
View article: Supplementary Figure S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in post-menopausal women.
View article: Supplementary Figure S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
CONSORT diagram.
View article: Supplementary Table S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Main subject characteristics at baseline (n = 406)
View article: Supplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Time-course of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 molar ratio in all women.
View article: Supplementary Table S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Mean event rate (per 1000 person-years) stratified by treatment arm, menopausal status, and baseline E2, SHBG, E2/SHBG ratio at 10 years of follow-up.
View article: Supplementary Table S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Mean event rate (per 1000 person-years) stratified by treatment arm, menopausal status, and baseline IGF-I, IGFBP-3, IGF-I/IGFBP-3 at 10 years of follow-up.
View article: Supplementary Figure S5 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S5 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Kaplan-Meier estimates of cumulative incidence of breast cancer events stratified by baseline biomarker levels and treatment arms.
View article: 269P Association of alcohol consumption on breast cancer incidence and prognosis: A systematic review and meta-analysis
269P Association of alcohol consumption on breast cancer incidence and prognosis: A systematic review and meta-analysis Open
View article: 154P Characteristics and outcomes of young BRCA carriers with triple-negative breast cancer (TNBC) according to histology subtype
154P Characteristics and outcomes of young BRCA carriers with triple-negative breast cancer (TNBC) according to histology subtype Open
View article: 268P Association between baseline body mass index and survival outcomes in BRCA carriers with breast cancer diagnosed at a young age: Results from an International cohort study
268P Association between baseline body mass index and survival outcomes in BRCA carriers with breast cancer diagnosed at a young age: Results from an International cohort study Open
View article: Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial Open
Purpose: Low-dose tamoxifen 5 mg/day (babytam) for 3 years can decrease the incidence of new breast cancer events in women with breast intraepithelial neoplasia by 42% with limited toxicity, which provides a new treatment option for these …
View article: Physicians’ knowledge, practice, and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: results of the ABC6 and ABC7 survey
Physicians’ knowledge, practice, and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: results of the ABC6 and ABC7 survey Open
Our survey showed that many concerns exist when discussing and dealing with fertility and pregnancy-related issues in patients with advanced breast cancer. It is essential to increase physicians' awareness on how to address fertility and p…
View article: Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status Open
PURPOSE To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA gene ( BRCA1 v BRCA2 ) and the association of the timing of genetic testing (before v at diagnosis) with prognosis. METHODS…
View article: Adverse events and impact on quality of life of antibody‐drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta‐analysis
Adverse events and impact on quality of life of antibody‐drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta‐analysis Open
Background Antibody‐drug conjugates are novel effective therapies for metastatic breast cancer. Nevertheless, their toxicity profile can significantly affect patients' quality of life over time. Methods This is a systematic review and meta…
View article: Prognostic implications of risk definitions from the monarchE and NATALEE trials
Prognostic implications of risk definitions from the monarchE and NATALEE trials Open
Background The monarchE and NATALEE trials employed different high-risk inclusion criteria. The main objective is to assess prognostic differences based on their inclusion criteria. Methods Patients with hormone receptor-positive/HER2-nega…
View article: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world Open
View article: Assisted Reproductive Technology in Young Brca Carriers with a Pregnancy after Breast Cancer: An International Cohort Study
Assisted Reproductive Technology in Young Brca Carriers with a Pregnancy after Breast Cancer: An International Cohort Study Open
View article: Comparison of Suboptimal Versus Adequate Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer Treated with Adjuvant Endocrine Therapy: An Exploratory Analysis of Two Prospective Studies
Comparison of Suboptimal Versus Adequate Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer Treated with Adjuvant Endocrine Therapy: An Exploratory Analysis of Two Prospective Studies Open